Javascript must be enabled to continue!
Comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in ICU patients: a propensity score-matched cohort study
View through CrossRef
Abstract
Background
Regional citrate anticoagulation (RCA) is the gold standard of anticoagulation for continuous renal replacement therapy but is rarely used for intermittent hemodialysis (IHD) in ICU. Few studies assessed the safety and efficacy of RCA during IHD in ICU; however, no data are available comparing RCA to heparin anticoagulation, which are commonly used for IHD. The aim of this study was to assess the efficacy and safety of RCA compared to heparin anticoagulation during IHD.
Methods
This retrospective single-center cohort study included consecutive ICU patients treated with either heparin anticoagulation (unfractionated or low-molecular-weight heparin) or RCA for IHD from July to September in 2015 and 2017. RCA was performed with citrate infusion according to blood flow and calcium infusion by diffusive influx from dialysate. Using a propensity score analysis, as the primary endpoint we assessed whether RCA improved efficacy, quantified with Kt/V from the ionic dialysance, compared to heparin anticoagulation. The secondary endpoint was safety. Exploratory analyses were performed on the changes in efficacy and safety between the implementation period (2015) and at long term (2017).
Results
In total, 208 IHD sessions were performed in 56 patients and were compared (124 RCA and 84 heparin coagulation). There was no difference in Kt/V between RCA and heparin (0.95 ± 0.38 vs. 0.89 ± 0.32;
p
= 0.98). A higher number of circuit clotting (12.9% vs. 2.4%;
p
= 0.02) and premature interruption resulting from acute high transmembrane pressure (21% vs. 7%;
p
= 0.02) occurred in the RCA sessions compared to the heparin sessions. In the propensity score-matching analysis, RCA was associated with an increased risk of circuit clotting (absolute differences = 0.10, 95% CI [0.03–0.18];
p
= 0.008). There was no difference in efficacy and safety between the two time periods (2015 and 2017).
Conclusion
RCA with calcium infusion by diffusive influx from dialysate for IHD was easy to implement with stable long-term efficacy and safety but did not improve efficacy and could be associated with an increased risk of circuit clotting compared to heparin anticoagulation in non-selected ICU patients. Randomized trials to determine the best anticoagulation for IHD in ICU patients should be conducted in a variety of settings.
Title: Comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in ICU patients: a propensity score-matched cohort study
Description:
Abstract
Background
Regional citrate anticoagulation (RCA) is the gold standard of anticoagulation for continuous renal replacement therapy but is rarely used for intermittent hemodialysis (IHD) in ICU.
Few studies assessed the safety and efficacy of RCA during IHD in ICU; however, no data are available comparing RCA to heparin anticoagulation, which are commonly used for IHD.
The aim of this study was to assess the efficacy and safety of RCA compared to heparin anticoagulation during IHD.
Methods
This retrospective single-center cohort study included consecutive ICU patients treated with either heparin anticoagulation (unfractionated or low-molecular-weight heparin) or RCA for IHD from July to September in 2015 and 2017.
RCA was performed with citrate infusion according to blood flow and calcium infusion by diffusive influx from dialysate.
Using a propensity score analysis, as the primary endpoint we assessed whether RCA improved efficacy, quantified with Kt/V from the ionic dialysance, compared to heparin anticoagulation.
The secondary endpoint was safety.
Exploratory analyses were performed on the changes in efficacy and safety between the implementation period (2015) and at long term (2017).
Results
In total, 208 IHD sessions were performed in 56 patients and were compared (124 RCA and 84 heparin coagulation).
There was no difference in Kt/V between RCA and heparin (0.
95 ± 0.
38 vs.
0.
89 ± 0.
32;
p
= 0.
98).
A higher number of circuit clotting (12.
9% vs.
2.
4%;
p
= 0.
02) and premature interruption resulting from acute high transmembrane pressure (21% vs.
7%;
p
= 0.
02) occurred in the RCA sessions compared to the heparin sessions.
In the propensity score-matching analysis, RCA was associated with an increased risk of circuit clotting (absolute differences = 0.
10, 95% CI [0.
03–0.
18];
p
= 0.
008).
There was no difference in efficacy and safety between the two time periods (2015 and 2017).
Conclusion
RCA with calcium infusion by diffusive influx from dialysate for IHD was easy to implement with stable long-term efficacy and safety but did not improve efficacy and could be associated with an increased risk of circuit clotting compared to heparin anticoagulation in non-selected ICU patients.
Randomized trials to determine the best anticoagulation for IHD in ICU patients should be conducted in a variety of settings.
Related Results
Impact of Common Anticoagulants on Complete Blood Count Parameters Among Humans
Impact of Common Anticoagulants on Complete Blood Count Parameters Among Humans
Abstract
Introduction
Among the most frequently used anticoagulants in hematological testing are tetra-acetic acid (EDTA), sodium citrate, and sodium heparin. However, there is a n...
Oxygen management in New Zealand and Australian intensive care units: A knowledge translation study
Oxygen management in New Zealand and Australian intensive care units: A knowledge translation study
<p><b>Background: Knowledge translation literature shows a delay between publication and uptake of research findings into clinical practice. There is uncertainty about ...
Oxygen management in New Zealand and Australian intensive care units: A knowledge translation study
Oxygen management in New Zealand and Australian intensive care units: A knowledge translation study
<p><b>Background: Knowledge translation literature shows a delay between publication and uptake of research findings into clinical practice. There is uncertainty about...
JIT 2023 - Jornadas de Jóvenes Investigadores Tecnológicos
JIT 2023 - Jornadas de Jóvenes Investigadores Tecnológicos
Es un honor presentar este libro que compila los trabajos de investigación y desarrollo presentados en las Jornadas de Jóvenes Investigadores Tecnológicos (JIT) 2023. Este evento s...
Novel ELISA-Based Assay for Detection of Complement Activation By PF4/Heparin Complexes
Novel ELISA-Based Assay for Detection of Complement Activation By PF4/Heparin Complexes
Abstract
The immune response to platelet factor 4 (PF4)/heparin complexes is a frequent iatrogenic complication of heparin therapy associated with development of hep...
HEPARIN BINDING TO HUMAN MONOCYTES: MODULATION BY HISTIDINE-RICH GLYCOPROTEIN
HEPARIN BINDING TO HUMAN MONOCYTES: MODULATION BY HISTIDINE-RICH GLYCOPROTEIN
Heparin and its related glycosaminoglycans interact with a variety of cell types and, irrespective of their anticoagulant activities, have a complex and biologically important infl...
The Efficacy of Taurolidine Citrate Solution v Heparin Lock Solution Instilled in Catheter Lumens of End Stage Renal Disease
The Efficacy of Taurolidine Citrate Solution v Heparin Lock Solution Instilled in Catheter Lumens of End Stage Renal Disease
Background: Hemodialysis patients with end-stage renal illness use a tunnelled central vein catheter for vascular access. Heparin with a preservative, in contrast, exhibits inferio...
Experimental study on a new type citrate anticoagulant hemodialysate in dogs
Experimental study on a new type citrate anticoagulant hemodialysate in dogs
Objective:
In this study, we initiated a new hemodialysate with citrate buffer, observed the factors that influence the citrate concentration of solution in hollow fiber...

